Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
In last year at 180, out now at 66.
Been a disappointing experience and off to try pastures new.
One thing I have learnt with this message board is not to listen the constant ramping by some posters who claim they top up on every drop. I know this for a fact now...
And posters who are hailed as derampers are more than likely the voice of reason.
A big eye opener for me, good luck to the rest of you.
https://www.google.com/url?q=https://**************Mcz-pBtLENzBfZGjdk1Byw&sa=D&source=editors&ust=1614854874798000&usg=AFQjCNG_UW4x8fbddYnuur6UXHf2FD4QRA
Unexpected but great news
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has entered into a Master Translational Research Services Agreement ("Agreement") with the University of Pennsylvania ("Penn"). The goal of the Agreement is to advance the Chimeric Antigen Receptor ("CAR") T-cells ("HEMO-CAR-T") developed by the Company toward and through clinical trials.
Under the Agreement, the Company will retain Penn to conduct translational research activities in support of the research being performed under the existing Sponsored Research Agreement ("SRA"), which was announced on August 11, 2020. As with the research being performed under the SRA, the research and development activities contemplated by the Agreement (the "R&D Activities") will involve Saar I. Gill, MD, PhD, an assistant professor of Medicine, a hematologist-oncologist physician scientist and scientific co-director of the Cell Therapy and Transplantation program in the Perelman School of Medicine at the University of Pennsylvania. Dr. Gill's laboratory is part of the Center for Cellular Immunotherapies ("CCI") at Penn. The Agreement governs the R&D Activities of various organizations within Penn and coordinates such R&D Activities with the work of the Company. The intended outcome of the complex of activities under the Agreement is the clinical proof of concept for HEMO-CAR-T, including its variations such as SAFE-HEMO-CAR-T, for the treatment of acute myeloid leukemia ("AML").
The R&D Activities are intended to include:
i. vector manufacturing for the delivery of HEMO-CAR-T to the patient's T-cells;
ii. an investigational new drug ("IND") filing for permission to conduct clinical trials; and
iii. clinical manufacturing of patient-specific HEMO-CAR programmed T-cells
Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "This is the next incredibly important step on a direct path to clinical proof of concept for one of our leading product candidates. We are very pleased to be collaborating with Penn, which was the first institution to develop CAR-T technology into an approved treatment for leukemias, and which has already saved so many lives. We are confident that this collaboration will further accelerate the development of our CAR-T product candidate, which we believe will have a significant and positive impact in the treatment of acute myeloid leukemia, for which there is currently no real effective treatment."